Relevant bibliographies by topics / Cervix uteri Cancer Victoria Diagnosis

Academic literature on the topic 'Cervix uteri Cancer Victoria Diagnosis'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cervix uteri Cancer Victoria Diagnosis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cervix uteri Cancer Victoria Diagnosis"

1

Chen, J., O. K. MacDonald, and D. K. Gaffney. "Population-based study of the incidence, mortality and prognostic factors of small cell carcinoma of the cervix: Analysis of the Surveillance, Epidemiology and End Results database." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 5546. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.5546.

Full text
Abstract:
5546 Background: Small cell carcinoma (SmC) is a rare histology of the cervix uteri that is generally associated with a poor prognosis. This is a population-based study of SmC using the Surveillance, Epidemiology and End Results (SEER). Methods: From 1977 to 2003, 290 women with SmC of the cervix uteri were identified. In addition, 27,527 patients with squamous cell carcinoma (SC) and 5231 with adenocarcinoma (AC) of the cervix were identified for comparison. The annual incidence of each histology was determined and examined for trend. The patient and disease characteristics at diagnosis were examined for each histology, and prognostic factors were evaluated for SmC. Mortality rates of SmC and other histologies were compared via log-rank tests. Results: Mean annual incidence of SmC was 0.03 per 100,000 women compared to 3.5 and 0.62 for SC and AC. A significant change in incidence was identified for SC and AC (p<0.05), but not for SmC (p=0.595). Patients with SmC were more likely to be treated with radiotherapy and to present with more advanced stage, lymph node involvement and distant metastasis than SC and AC (p<0.05). Survival rates for SmC at 2 and 5 years were 46.8% and 35.7%, which were worse compared to SC (HR 0.45; 95% CI: 0.36–0.57) and AC (HR 0.31; 95% CI: 0.25–0.39). The difference in survival is predominantly in patients with early stage, localized disease, and those treated with surgery ( Table ). Multivariate analysis of SmC, race, FIGO stage, age and hysterectomy alone significantly impacted prognosis (p<0.05), while year of diagnosis, lymph node involvement, tumor size, marital status and other treatment modality did not. Conclusions: SmC is an uncommon histologic variant of cervix cancer associated with a worse prognosis compared to SC and AC with a predilection for metastasis at diagnosis. FIGO stage, age and race are prognostic factors for survival. [Table: see text] No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
2

Zhang, Fang, Min Shi, Na Zhao, Peng Guo, Jun Hou, and Yang Liu. "Whole exome sequencing facilitated diagnosis of patients with multiple mucinous neoplasms of the female genital tract." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e17513-e17513. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e17513.

Full text
Abstract:
e17513 Background: The differential diagnosis is challenging in clinical practice, especially among gastric-type AD of the cervix with ovarian metastases, multiple primary mucinous neoplasm in cervix and ovary, and synchronous mucinous metaplasia and neoplasia of the female genital tract (SMMN-FGT). Previous studies have revealed that next-generation sequencing might be a feasible tool in identifying the origin of tumor. Herein, whole exome sequencing (WES) was performed to distinguish patients with metastatic disease. Methods: WES analysis was performed on 28 tumors and 7 normal tissues derived from 8 patients. Each patient had one lesion of the cervix uteri. Most of them had lesions at other anatomical sites, including corpus uteri, ovary, oviduct, vermiform appendix and omentum. Mutations signatures and clonal evaluation inferred from single-nucleotide/copy number variants were explored. Results: Previous studies of multiple types of cancer have identified more than 40 single-base substitution (SBS) signatures. SBS3/6 referring to defective DNA mismatch repair and SBS10 reported in both uterus and colorectal AD were significantly enriched in this study. Next, we found no significant distribution of SBS3/6/10 among tumors at different anatomical sites. These findings indicate that primary cervical/ovarian AD with metastases other than multiple primary cancers was the predominant histology in 8 patients. The association of genomic alterations in POLE/ POLD1/HRR pathway with the distribution of SBS signatures was explored. SBS3 had a trend of significant distribution (p = 0.01) in four patients who had germline alterations in HRR pathway. Furthermore, SBS10 was significantly enriched (p = 0.009) in 2 patients with germline POLE/POLD1 alterations. Clonal evolution analyses revealed that 2 patients were identified as having SMMN-FGT, and other 6 patients had dominant clones in different tumors, which suggested a . Notably, besides the dominant clones and subclones, some tumors also exhibited extra independent clones, which might be the mixed histology of primary and metastatic tumor. In addition, we found the difference of overall survival in patients having gastric-type AD of the cervix with ovarian metastases and cervical AD patients with different FIGO stage disease based on SEER database data. Conclusions: Our study demonstrated that WES might be a feasible tool to distinguish patients having primary cervical AD with multiple metastases from those with multiple primary cancers of the female genital tract, which suggests that WES proved valuable in facilitating the diagnostic workup. A prospective, multi-center, large cohort study is needed to investigate the performance of WES in identifying the origin of tumors in patients with multiple tumors of the FGT.
APA, Harvard, Vancouver, ISO, and other styles
3

Muhammad Aminu, Baffah, Lamaran Makama Dattijo, Kabir Abdullahi, and Calvin Chama. "Polypectomy as a Complete Therapy for Leiomyosarcoma of the Cervix Uteri: An Unusual Treatment." International Journal of Women's Health and Reproduction Sciences 7, no. 3 (November 10, 2017): 412–14. http://dx.doi.org/10.15296/ijwhr.2019.68.

Full text
Abstract:
Objectives: Leiomyosarcoma (LMS), which arises from the uterine cervix, is an extremely rare neoplasm and is presented with vaginal bleeding and discharge. In our case report, we intended to highlight the role of polypectomy as a practical option for routine hysterectomy and the surgical cure of cervical LMS. Case Report: A 50-year-old woman (Para 8+0, 6A) presented to the Gynecological Clinic of ATB University Teaching Hospital with vaginal discharge and fleshy mass protruding from the vulva. Examination revealed a cervical polyp on the anterior lip of the cervix. Polypectomy was performed subsequently, and histologic examination including immunohistochemical staining confirmed LMS of the uterine cervix. The patient underwent hysterectomy with bilateral salpingo-oophorectomy with the histological confirmation of a complete excision. Conclusions: Generally, no specific management option is taken for this tumor due to its rare occurrence. However, polypectomy with a wide excision of tumor margin could result in a complete cure, and prolonged survival as in the case presented. Accordingly, histological studies including special stainings may play a vital role in cancer diagnosis.
APA, Harvard, Vancouver, ISO, and other styles
4

Singh, Abha, Avinashi Kujur, Renuka Gahine, and Rashmi Tiwari. "Prevalence of occult gynecological cancer in women undergoing surgeries for benign indications in a tertiary healthcare center of Chhattisgarh." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 10, no. 3 (February 24, 2021): 1120. http://dx.doi.org/10.18203/2320-1770.ijrcog20210745.

Full text
Abstract:
Background: Hysterectomy, the surgical removal of uterus, is 2nd most frequently performed major surgical procedures on women,with90% of hysterectomies are performed for benign indications. However, there may be cases in which malignancy or premalignant lesions which are only confirmed on histopathology are defined as occult malignancy.Methods: We conducted a prospective observational study on a cohort of women undergoing various gynaecological surgeries for benign indications in a time period of January 2019 to January 2020 in the Department of obstetrics and gynaecology, Dr. BRAM hospital and Pt. J. N. M. medical college, Raipur (C.G) to find out the prevalence of occult pre malignant and malignant lesions.Results: Of 132 women who underwent surgeries for benign gynecological indications, based on final histopathological report, prevalence of occult premalignant lesion was 11.36% (95% CI 5.7-16.3%) and prevalence of occult malignancy was 2.27% (95% CI 0.2 -4.8%). Prevalence of occult premalignant lesion of corpus uteri and cervix uteri was 2.3 and 9.1% respectively. No occult premalignant lesion of ovary was found. Prevalence of occult malignant lesion of corpus uteri and ovary was 1.5 and 0.75% respectively.Conclusions: We observed that even after complete preoperative workup only 72.7% of the preoperative clinical diagnoses were correlated with their histopathological diagnosis. Thus, while making the diagnosis, risk factors along with standard preoperative approach should be strongly adhered to prevent misdiagnosis and to prevent missing of any pre malignant or malignant findings.
APA, Harvard, Vancouver, ISO, and other styles
5

Khanna, Divya, Naveen Chandrahas Khargekar, and Ajay Kumar Khanna. "Implementation of Early Detection Services for Cancer in India During COVID-19 Pandemic." Cancer Control 27, no. 1 (January 1, 2020): 107327482096047. http://dx.doi.org/10.1177/1073274820960471.

Full text
Abstract:
Early detection of cancer greatly increases the chances of better survival. The emergence of COVID-19 pandemic has disrupted several essential health services globally and early detection of cancer services is one of them. The routine cancer screenings have plummeted in many developed countries since the crisis. India has highest estimated lip and oral cavity cancer cases worldwide (119,992, 33.8%) and the secondhighest number of breast (162,468, 17.8%) and cervix uteri (96,922,30.7%) cancers in Asian sub-continent. Not only India has high burden of cancer, but the majority (75-80%) of patients have advanced disease at the time of diagnosis. Hence is it imperative that early detection services should be kept functional at out-patient settings so that at least the patients coming to hospitals with early signs and symptoms can be diagnosed as early as possible. Strategies need to be adopted to continue early detection services and ensure safety of patients and health care workers from COVID-19 transmission.
APA, Harvard, Vancouver, ISO, and other styles
6

Smirnov, Y. A., T. M. Bogacheva, and R. G. Valeev. "Ultrasonography in assessing the cervical cancer extent." Kazan medical journal 93, no. 5 (October 15, 2012): 735–38. http://dx.doi.org/10.17816/kmj1699.

Full text
Abstract:
Aim. To study the potentials of complex ultrasonography in assessing the extent of cervical cancer, defining typical ultrasonographic features of cervical cancer. Methods. 75 patients with the diagnosis of morphologically confirmed cervical cancer were examined. Continuous sampling method was used to recruit the patients. Patients underwent transabdominal, transvaginal and transrectal ultrasonography with the use of color Doppler and power Doppler modes. Results. 57 (76,5%) patients were diagnosed with squamous cell non-keratinous carcinoma, 12 (16%) - with squamous cell keratinous carcinoma, 6 (8%) - with adenocarcinoma. 43 (57,3%) patients had cancer stages I-II, 32 (42,7%) - cancer stages III-IV. The certain features of ultrasonographic images were found at different stages of cervical cancer. At cancer stage I the most typical findings were: low echogenicity area, diffuse heterogeneity of stroma, area of hypervascularity at the place of cervical cancer. Increased blood flow at the cancer site is typical for cervical cancer because of tumor vasculature hyperplasia and neoangiogenesis, the increase in number of blood vessels is proportional to tumor size. Cervix hypertrophy, fuzzy and irregular contouring, no flexion angle between the fundus and cervix were characteristic for cervical cancer stages II-III. Corpus uteri echo-structure at the tumor site portrays the tumor structure. Infiltrates in parametrium can be seen. At stage IV tumor spreads to urine bladder and rectum walls. In advanced stages uretеrs can be involved, pyelectasis and ureterectasis can develop. Conclusion. Complex ultrasonography allows to diagnose cervical cancer quite reliably and to estimate the extent of cervical cancer.
APA, Harvard, Vancouver, ISO, and other styles
7

Khullar, Nandika, Tejbir Singh, Mohan Lal, and Jasleen Kaur. "Impact of cancer diagnosis on different aspects of life of patients of cancer breast and cancer cervix uteri: a cross sectional study at Government Medical College, Amritsar, Punjab." International Journal Of Community Medicine And Public Health 5, no. 5 (April 24, 2018): 2053. http://dx.doi.org/10.18203/2394-6040.ijcmph20181722.

Full text
Abstract:
Background: Advancements in understanding about the etiology and pathogenesis of cancer has led to increased awareness regarding the clinical course of disease and its appropriate treatments. This is the major reason behind longer life expectancy in cancer patients. However, this longer life is not necessarily an easy one due to debilitating nature of both the disease and its treatment modalities. This study was done to assess the impact of cancer diagnosis on the psycho-social aspects of patient’s lives.Methods: All patients of cancer breast and cancer of cervix uteri, who reported between January 1, 2013 to December 31, 2015; at Radiotherapy Department, Guru Nanak Dev Hospital, Government Medical College, Amritsar and were residents of Amritsar District, were listed and a total of 127 patients were included in the study. Patients were interviewed using a pre-tested, pre-designed questionnaire at their place of residence.Results: Assessing the demands of the altered lives of cancer patients in different aspects like modifications in daily living, loss of work and pleasure, reformed religious/spiritual opinions, social support received etc. It is seen that social life of patients is affected after diagnosis of cancer. However, social support received by the patients and families is similar as compared to before diagnosis.Conclusions:Maximal impact of cancer, its diagnosis and treatment is on various aspects of the life of patients not only immediate family but relatives, friends and neighbours lend psychological, social and economic support in such situations which helps a cancer survivor cope with the trauma and carry on with their lives.
APA, Harvard, Vancouver, ISO, and other styles
8

Sparén, P., L. Gustafsson, L. G. Friberg, J. Pontén, R. Bergström, and H. O. Adami. "Improved control of invasive cervical cancer in Sweden over six decades by earlier clinical detection and better treatment." Journal of Clinical Oncology 13, no. 3 (March 1995): 715–25. http://dx.doi.org/10.1200/jco.1995.13.3.715.

Full text
Abstract:
PURPOSE Cancer of the cervix uteri can be controlled by cytologic screening for the detection of precursor lesions, but such intervention remains unrealistic in many countries in which this cancer is common. The possibility of reducing mortality by earlier clinical detection, followed by basic therapy, has never been properly assessed. PATIENTS AND METHODS We compiled records of incident cases of invasive cancer of the cervix diagnosed in a defined area of Sweden from 1930 through 1990. In a cohort of 6,044 women, we analyzed temporal trends in incidence and survival by clinical stage and age at diagnosis. Generalized proportional hazards models were used to study several factors simultaneously and quantify the overall reduction in mortality. RESULTS For each successive stage at diagnosis, the overall risk of dying increased 2.5-fold (95% confidence interval [CI], 2.4 to 2.7). From 1930, a marked improvement in stage distribution was accompanied by increasing survival rates in stages I and II disease. These changes largely took place before the introduction of screening and external-beam radiation. The 10-year relative survival rate increased from 33% in the 1930s to approximately 55% in the 1950s and thereafter. CONCLUSION Improvements in public and professional awareness of cervical cancer resulted in diagnoses at earlier clinical stages. The rate of cure in early stages improved when basic local treatment was introduced, but only little of the progress was attributable to the introduction of more advanced treatment technologies. These findings offer considerable hope for a substantial reduction in the mortality of cervical cancer without cytologic screening, even in countries with limited resources.
APA, Harvard, Vancouver, ISO, and other styles
9

Liu, Jiaqing, Huaqiang Zhou, Yaxiong Zhang, Wenfeng Fang, Yunpeng Yang, Shaodong Hong, Gang Chen, et al. "Impact of prior cancer history on the overall survival of younger patients with lung cancer." ESMO Open 5, no. 1 (February 2020): e000608. http://dx.doi.org/10.1136/esmoopen-2019-000608.

Full text
Abstract:
BackgroundPatients with a history of prior cancer are frequently excluded from cancer trials. Previous studies indicated that prior cancer does not adversely impact clinical outcomes for patients with lung cancer older than 65 years. However, it remains unknown whether these results are applicable to patients with lung cancer aged younger than 65 years old. The study aimed to investigate the impact of prior cancer history on younger patients with lung cancer.MethodsWe identified younger patients with lung cancer (<65 years) diagnosed between 2004 and 2009 in the Surveillance, Epidemiology, and End Results database. Propensity score matching was performed to balance differences in baseline characteristics between groups. Kaplan-Meier method and the Cox proportional hazards model were used to evaluate the impact of prior cancer on overall survival (OS).ResultsAmong 103 370 eligible patients with lung cancer, 15.18% had a history of prior cancer. Lung and bronchus (25.83%), breast (14.13%), prostate (8.85%) and cervix uteri (4.74%) were the most common prior cancer types. Of prior cancers, 61.56% are localised and regional stages. More than 67.98% of prior cancers were diagnosed within 5 years of the index lung cancer diagnosis. The median times of diagnosis for prior cancers were 38 months. Patients with prior cancer had the same/non-inferior OS as that of patients without a prior cancer diagnosis (propensity score-adjusted HR=1.01, 95% CI=0.99 to 1.04, p=0.324). Subgroup analyses stratified by timing of prior cancer displayed almost the same tendency (p>0.05). Interestingly, early-stage patients with a history of prior cancer had adverse survival curves (p<0.05). Advanced-stage patients with prior cancer had non-inferior survival (p>0.05).ConclusionsA prior cancer diagnosis has a heterogeneous effect on the survival of patients with lung cancer aged <65 years across different stages, but further prospective studies are still warranted.
APA, Harvard, Vancouver, ISO, and other styles
10

Vercelli, Marina, Alberto Quaglia, Claudia Casella, Lucia Mangone, Arduino Verdecchia, Riccardo Capocaccia, Roberta De Angelis, et al. "Cancer Patient Survival in the Elderly in Italy." Tumori Journal 83, no. 1 (January 1997): 490–96. http://dx.doi.org/10.1177/030089169708300111.

Full text
Abstract:
Aims and background Italy, like most western populations, is sharply aging and changing its age structure with a striking increase in the oldest segment of the elderly. Since age is related to an exponential growth of cancer incidence rates and to a worsening of prognosis, the progressive aging of the population will constitute, in the future, an issue increasingly more important for public health. The present study is the first effort to present and analyze survival rates in Italian elderly cancer patients in order to provide a starting point for the development of better clinical strategies addressed to the aged. Materials and methods The presented data come from a large data set consisting of survival data relating to 25,798 men and 20,479 women, aged 65–84 years at diagnosis, collected by Italian cancer registries participating in the ITACARE project. Relative survival rates of patients have been calculated by sex, quinquennial age classes and the considered entire age class for overall malignant neoplasms and the 10 most frequent cancer sites in the elderly. Results When all Italian data for all cancers in the 65–84 year age group were pooled, survival rates at 5 years from the diagnosis was 27% and 39% in men and women, respectively. As regards specific sites, survival rates below 50% were observed for lung, stomach and ovary cancer at 1 year from diagnosis. At 5 years from diagnosis, the rates were less than 50% for colon, prostate, cervix, multiple myeloma, non-Hodgkin's lymphoma and melanoma (only in men). The best survival at 5 years from diagnosis (above 50%) was in women for melanoma and corpus uteri and breast cancer. For all cancers, the prognosis for women was better in each considered age group even though a dramatic decrease in survival with age was observed in both sexes. In general, a similar decline in survival with increasing age characterized all considered specific sites. However, at closer observation, the patterns of a decrease revealed some differences. The ratio between the survival rates of 55–64 vs 65–84 year age class indicated that the sites with the greatest advantage of survival for younger patients (ratio >1.5) were ovary, lung and melanoma (only in men), whereas the least advantage was observed for colon, corpus uteri, breast and prostate. By calendar periods, excluding non-Hodgkin's lymphoma for women, an increase in survival was observed for all considered sites, improving an encouraging successful trend in diagnostic and therapeutic progresses.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cervix uteri Cancer Victoria Diagnosis"

1

Cheung, Nga-yin Annie, and 張雅賢. "Cervical cancer screening: evolution from Paptest to molecular markers." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46540465.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Galbraith, Kevin. "Cervical cancer screening in Hong Kong : addressing inequity /." Thesis, Click to view the E-thesis via HKUTO, 2005. http://sunzi.lib.hku.hk/hkuto/record/b39724104.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kee, Francis, and 紀思思. "Cervical screening programme : 10 years of success or failure?" Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206964.

Full text
Abstract:
Cervical cancer is the ninth leading cause of female cancer deaths in Hong Kong. In 2011, 391 new cases of cervical cancer were diagnosed and the age-standardized incidence rate was 7.2 per 100,000 standard populations. In 2012, 133 women died from this cancer, accounting for 2.5% of female cancer deaths. The age-standardized death rate of cervical cancer was 2.1 per 100,000 standard populations. Human papillomavirus (HPV) infection is an established cause of cervical cancer. HPV vaccines offer more than 70% protection for women against HPV types 16 and 18 infections and their related cervical precancerous lesions and cervical cancer. As there are usually no symptoms in high-risk HPV infection, it is often diagnosed at a late stage. Regular cervical smears can offer early detection of pathological changes and pre-cancerous stage for a timely medical treatment to prevent progression to cervical cancer. The Cervical Screening Programme (CSP) of Department of Health (DH) was launched on 8 March 2004. It is a voluntary program with the objectives to increase the population coverage of cervical screening among women and to reduce the incidence and mortality of cervical cancer in Hong Kong. Women participating in the programme are encouraged to have cervical smears in the medical centres of their own choices and to provide their cervical smear information through their health care providers to the central registry of the CSP - The Cervical Screening Information System (CSIS). As at 31 December 2013, 491,674 women have registered with CSP. When DH implemented CSP in March 2004, a report was published in the same year showing evidence that an organized screening compared with the opportunistic screening could substantially increase benefits and reduce costs. Another local study conducted early this year supported by the Health Services Research Fund also highlighted the importance and urgency in enhancing the current screening protocol. It is of public health interests to study and compare the programme outcomes with countries like Finland, Australia, UK and Japan where different policy was adopted for the prevention of cervical cancer. Information gathered from research papers on epidemiological studies has been collected and analyzed on population benefit (outcome, access, disparities), cost (cost benefit, efficiency, cost containment), equity, feasibility and constituency perspectives in formulation of the policy alternatives. In conclusion, strengthening what is already in place with better allocative efficiency could protect the female population against cervical cancer. From the education perspective, emphasis on the risk of HPV infection in the sex education curriculum would raise the awareness on the precaution of HPV infections amongst young females. Additionally, vaccination at the age of 12 can provide protection against most types of HPV. It is strongly recommended that a cervical screening and HPV co-testing strategy at a triennial interval could provide the best cost and benefit effectiveness. Together they can enhance protection coverage of women at 12 through immunization and from 25 - 64 through active population screening. The ultimate objectives to reduce incidence, mortality and increase coverage could be achieved.
published_or_final_version
Public Health
Master
Master of Public Health
APA, Harvard, Vancouver, ISO, and other styles
4

Lai, Tung-on Anthony, and 黎東安. "PRKAA1 gene amplification in cervical cancer and precursors: a study in cytology samples." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2010. http://hub.hku.hk/bib/B45153048.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kwan, Tak-ching Tracy, and 關德貞. "Human papillomavirus testing in cervical cancer screening: potential harms and implications for intervention." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B4658836X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ho, Wing-lun, and 何穎麟. "Application of an automated DNA-imager in cervical cancer screening." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206506.

Full text
Abstract:
In cervical screening programmes, Papanicolaou test (Pap test) is the key screening tool. However Pap test is difficult to implement in low-resource region. Introduction of an economic, cost-effective and less skill demanding equipment is hence a potential direction of advance in cervical screening methodology. 　　Cervical carcinogenesis involves genetic instability which leads to chromosomal aneuploidy. Evaluation of aneuploidy may hence provide information for identifying cancer and precursor cells. An automated DNA-image-cytometry system (DNA-imager) capable of quantitating the DNA content of cells has recently been developed. 　　To evaluate the efficacy of DNA-imager in cervical cancer screening, a total of 483 residual ThinPrep liquid-based cytology (LBC) samples after diagnosis were retrieved and evaluated by the DNA-imager. The high risk human papillomavirus (HPV) status of the atypical squamous cells of undetermined significance (ASC-US) samples has been tested as a parallel study. According to established criteria, 423 out of the 483 samples were satisfactory for downstream analysis. The samples were designated “Normal”, “Suspicious” or “Abnormal” according to their DNA aneuploidy and proliferation activity. 　　Significantly more high grade lesion samples (HSIL and SCC) were designated as “Abnormal” by DNA-imager than were lower grade lesion samples (Negative, ASC-US, AGC, ASC-H, and LSIL) (94.19% vs 51.04%, p<0.0001). For detecting ≥HSIL, DNA-imager achieved high sensitivity and specificity (94.19% and 48.96%) using “Abnormal” as cut off. Adopting a more stringent definition of “Suspicious” or “Abnormal” would increase the sensitivity to 100% but decreased the specificity to 24.33%. 　　 　　Regarding ASC-US triage, DNA-imager achieved a sensitivity and specificity of 80.00% and 71.29% respectively when “Abnormal” was used as test positive to predict cases with ≥HSIL follow-up in the next two year. The sensitivity increased but the specificity decreased to 90.00% and 34.65% respectively if “Suspicious or above” was used as indicator of undesirable follow-up. HR-HPV test, on the other hand, was able to identify all cases with ≥HSIL upon follow-up (sensitivity = 100%) but the specificity was only 15.84%. Among these ASC-US sample, test positivity of the two tests showed poor concordance with each other (Cohen’s κ = 0.062 and 0.074 respectively for “Suspicious or above” or “Abnormal”, respectively). 　　Our findings suggested that DNA-imager may be a useful tool for automated primary screening of cervical cancer 3
published_or_final_version
Pathology
Master
Master of Medical Sciences
APA, Harvard, Vancouver, ISO, and other styles
7

Choi, Ka-man, and 蔡嘉敏. "Cost-effectiveness of primary HPV testing for cervical cancer screening : a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/193758.

Full text
Abstract:
Background: Human papillomavirus (HPV) DNA test is more sensitive and can detect more high-grade cervical intraepithelial lesions than cytology test in cervical cancer screening. There are studies confirming HPV test being more effective in cervical cancer screening by detecting the persistence of HPV infection that could lead to cancer. However, the costs associated with a HPV test is higher than a cytology test. Moreover, HPV test is less specific which could subject more women to further triage tests or unnecessary invasive diagnostic procedures. Therefore healthcare costs could possibly increase if primary HPV screening is to be adopted. Study objective: The aim of the study is to systematically review the cost-effectiveness of primary HPV testing in cervical cancer screening Method: Electronic search was performed in three biomedical databases (PubMed, Medline, Cochrane Library) and one economic evaluation database to identify relevant studies. Studies were selected according to the explicit inclusion and exclusion criteria defined. Only those studies carried out in high-income countries were included so that result could be better applied to Hong Kong. Results: A total of 19 studies were included in this systematic review. Cytology-only method is generally not cost-effective. To be cost-effective, it has to be performed in a longer screening interval which would reduce not only the screening costs but also a reduction in the health outcomes. Among the different options in HPV-based primary screening, HPV testing with cytology triage is the most cost-effective strategy in many of the studies. Combined HPV/cytology co-screening could achieve the biggest health benefit but is also most costly. HPV-based screening is more cost-effective for those >30 years of age and is usually less cost-effective if applied to young women. From the result in sensitivity analysis, HPV-based screening is sensitive to an increase in the costs of the HPV test, a low HPV test sensitivity and a low screening compliance rate. Conclusion: Primary HPV screening is cost-effective and generally performs better than cytology screening. The result of this systematic review guides the future direction of developing an optimal cervical screening strategy in Hong Kong. Local context has to be considered when examining the cost-effectiveness of primary HPV testing for cervical screening. Good quality local epidemiological data on HPV infection and cervical cancer and screening would be required to aid future research on the application of HPV test for cervical cancer screening in Hong Kong.
published_or_final_version
Public Health
Master
Master of Public Health
APA, Harvard, Vancouver, ISO, and other styles
8

Fallala, Muriel Selma. "Cervical cancer screening : safety, acceptability, and feasibility of a single-visit approach in Bulawayo, Zimbabwe." Thesis, Stellenbosch : Stellenbosch University, 2014. http://hdl.handle.net/10019.1/97187.

Full text
Abstract:
Thesis (MFamMed)--Stellenbosch University, 2014.
OBJECTIVE: The purpose of the study was to assess the safety, acceptability and feasibility of Visual Inspection with Acetic Acid and Cervicography (VIAC) followed by Cryotherapy or Loop Electrical Excision Procedure (LEEP) at a single visit for prevention of cancer of the cervix in Bulawayo, Zimbabwe. STUDY DESIGN: The study was descriptive using retrospective data extracted from electronic medical records of women attending the VIAC clinic at United Bulawayo Hospital in the period 1st February2010 to 31st December2012.Over 24 months 4641 women visited the clinic and were screened for cervical cancer using VIAC. If positive and eligible, cryotherapy or LEEP was offered immediately. Treated women were followed up at 3months and 1 year. RESULTS: The VIAC test positive rate was 10.8%.Of those eligible,17.0% received immediate cryotherapy, 44.1%received immediate LEEP, 1.9% delayed treatment and 37.0% were referred to a gynaecologist. No major complications were recorded after cryotherapy or LEEP. Among those treated99.5% expressed satisfaction with their experience. Only 3.2% of those treated at the clinic were VIAC positive one year later. The service was shown to be feasible to sustain over time with the necessary consumables. There were no service-related treatment postponements and the clinic staff and facility were able to meet the demand for the service. CONCLUSION: A single visit approach using VIAC, followed by cryotherapy or LEEP proved to be safe, acceptable and feasible in an urban African setting in Bulawayo, Zimbabwe.
AFRIKAANSE OPSOMMING: Geen opsomming beskikbaar.
APA, Harvard, Vancouver, ISO, and other styles
9

廖滿萍 and Moon-ping Liu. "Study of Pap smear attendance and the abnormal rate in the past ten years." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2002. http://hub.hku.hk/bib/B31970709.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sze, S. M. Candy, and 施少妹. "Evaluation and comparison of molecular diagnostic methods for detection of human papillomavirus (HPV) in relation to cervicalneoplasia." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B4501145X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cervix uteri Cancer Victoria Diagnosis"

1

Klein, Lori. Cervical cancer: January 1993 through March 1996 : 926 citations. Bethesda, Md: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Library of Medicine, Reference Section, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Klein, Lori. Cervical cancer: January 1993 through March 1996 : 926 citations. Bethesda, Md. (8600 Rockville Pike, Rockville 20894): U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Library of Medicine, Reference Section, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hirschmann, Kris. Cervical cancer. Detroit: Lucent Books, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

National Institutes of Health (U.S.). Lo que usted necesita saber sobre el cáncer de cérvix. Bethesda, Md.?]: Institutos Nacionales de la Salud, Instituto Nacional del Cáncer, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

W, Orr James, ed. Cancer of the cervix: Diagnosis and treatment. Edinburgh: Churchill Livingstone, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ahuja, Maninder. Precancerous lesions of cervix: Prevention, early diagnosis and management. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Committee, Australian Health Ministers' Advisory Council Cervical Cancer Screening Evaluation Steering. Cervical cancer screening in Australia: Options for change. Canberra: Australian Govt. Pub. Service, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ontario Medical Association. Ad Hoc Committee on Cervical Cancer Screening. Cervical cancer screening in Ontario: A report and recommendations from the OMA Ad Hoc Committee on Cervical Cancer Screening. Toronto, Ont: Ontario Medical Association, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

W, Orr James, ed. Cancer of the cervix. Philadelphia: Lippincott, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

GOVERNMENT, US. An Act to Amend Title XIX of the Social Security Act to Provide Medical Assistance for Certain Women Screened and Found to Have Breast or Cervical Cancer under a Federally Funded Screening Program to Amend the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with Respect to Surveillance and Information Concerning the Relationship between Cervical Cancer and the Human Papillomavirus (HPV), and for Other Purposes. [Washington, D.C: U.S. G.P.O., 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Cervix uteri Cancer Victoria Diagnosis' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography